[Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
Twenty-one patients suffering from Parkinson disease were treated with L-Dopa together with an extra-cerebral dopa-decarboxylase inhibitor (Ro4-4602) and with triesyphenidyl. Seven assessments of the patient's clinical condition were carried out over a period of two years with a number of neurological and psychometric tests. At the beginning of the second year of treatment, the signs and symptoms of Parkinson disease began to worsen with an increased disability. In the present paper two possibilities are discussed, namely whether the deterioration was the consequence of L-Dopa administration or whether this was simply the outcome of inadequacy of drug treatment during a period of natural worsening of the disease.
D000328:Adult; D000704:Analysis of Variance; D001545:Benserazide / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009127:Muscle Rigidity / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D011581:Psychological Tests; D014202:Tremor / Q000188:drug therapy
D006834:Hydrazines; D007980:Levodopa; D001545:Benserazide
Andamento della sindrome di Parkinson nel corso di terapia biennale con L-dopa associata a R04-4602